SHR 1918
Alternative Names: SHR-1918Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator Beijing Suncadia Pharmaceuticals
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperlipidaemia
Most Recent Events
- 04 Dec 2024 Beijing Suncadia Pharmaceuticals plans a phase III trial for Hyperlipoproteinaemia type II(Treatment experienced, In children, In adolescents, In adults, In the elderly) (SC, injection) in December 2024 (NCT06723652)
- 30 Aug 2024 Efficacy, pharmacokinetics and adverse event data from the phase I trial in Hyperlipidaemia presented at the Annual Congress of the European Society of Cardiology 2024 (ESC Congress 2024)
- 30 Jun 2024 Beijing Suncadia Pharmaceuticals plans a phase II trial for Hyperlipidaemia in China (SC, injection) in June 2024 (NCT06471218)